Cargando…

SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

INTRODUCTION: SHP656 is the first factor VIII (FVIII) product developed using polysialylation (PSA) technology, in which full‐length recombinant (r) FVIII (anti‐haemophilic factor [recombinant]) is conjugated with a 20 kDa PSA polymer. AIM: To compare the safety, immunogenicity and pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiede, Andreas, Allen, Geoffrey, Bauer, Alexander, Chowdary, Pratima, Collins, Peter, Goldstein, Brahm, Jiang, Hongyu Jeanne, Kӧck, Kathleen, Takács, István, Timofeeva, Margarita, Wolfsegger, Martin, Srivastava, Shouryadeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027936/ https://www.ncbi.nlm.nih.gov/pubmed/31778283 http://dx.doi.org/10.1111/hae.13878

Ejemplares similares

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
por: Traets, Marissa J.M., et al.
Publicado: (2020)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany
por: Olivieri, Martin, et al.
Publicado: (2020)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII
por: Swiech, Kamilla, et al.
Publicado: (2011)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
por: Chang, Chia-Yau, et al.
Publicado: (2023)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
por: Bullement, Ash, et al.
Publicado: (2021)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020)

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
por: Teare, John M, et al.
Publicado: (2019)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Polysialylated-neural cell adhesion molecule (PSA-NCAM) in the human trigeminal ganglion and brainstem at prenatal and adult ages
por: Quartu, Marina, et al.
Publicado: (2008)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
por: Bonanad, Santiago, et al.
Publicado: (2021)

A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
por: Jamal, Munirah, et al.
Publicado: (2023)

The NMR studies of CMP inhibition of polysialylation
por: Lu, Bo, et al.
Publicado: (2023)

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
por: Zerra, Patricia E., et al.
Publicado: (2020)

Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies
por: Lacroix-Desmazes, Sébastien, et al.
Publicado: (2021)

Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice—Brief Report
por: Ward, Soracha E., et al.
Publicado: (2023)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Polysialylation in a DISC1 Mutant Mouse
por: Takahashi, Yuka, et al.
Publicado: (2022)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin
por: Keipert, Christine, et al.
Publicado: (2020)

Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A
por: Huang, Kun, et al.
Publicado: (2022)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec
por: Zhang, Lening, et al.
Publicado: (2019)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Impact of polysialylated CD56 on natural killer cell cytotoxicity
por: Moebius, Jeannette M, et al.
Publicado: (2007)

Serum polysialylated neural cell adhesion molecule in childhood neuroblastoma.
por: Glüer, S., et al.
Publicado: (1998)

NCAM1 Polysialylation: The Prion Protein's Elusive Reason for Being?
por: Mehrabian, Mohadeseh, et al.
Publicado: (2016)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood
por: Zhang, Lening, et al.
Publicado: (2022)

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
por: Wang, Michael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_18j8m5v9ah0nceepfq7mcrjsot